The European Commission (EC) has approved a new treatment approach for Eylea (aflibercept) for patients with neovascular age-related macular degeneration (nAMD).
This new regimen allows clinicians already in the first year of treatment to extend patients’ individual injection intervals based on visual or anatomic outcomes.
Michael Devoy, head of medical affairs and pharmacovigilance of Bayer’s Pharmaceuticals division and the company’s chief medical officer, said: “This new treatment regimen for Eylea has the potential to reduce the number of injections and clinic visits to less than four in the second year for certain nAMD patients, while still maintaining strong visual outcomes and the ability to see.”
Bayer has developed Eylea in collaboration with US biotech Regeneron Pharmaceuticals.
A Product Manager with expertise in pharma marketing and sales operations